Translate this page to:
In JoVE (1)
- Långsiktig kultur för mänskliga Prover bröstcancer och deras analys Använda optisk Projection Tomography
Other Publications (1)
This translation into Swedish was automatically generated.
English Version | Other Languages
Articles by Sarah E. Wedden in JoVE
Långsiktig kultur för mänskliga Prover bröstcancer och deras analys Använda optisk Projection Tomography
Alexander D. Leeper1, Joanne Farrell2, J. Michael Dixon1, Sarah E. Wedden2, David J. Harrison1, Elad Katz1
1Breakthrough Breast Cancer Research Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, 2MRC Technology
Vi har utvecklat en kollagenbaserade
Other articles by Sarah E. Wedden on PubMed
Determining Tamoxifen Sensitivity Using Primary Breast Cancer Tissue in Collagen-based Three-dimensional Culture
Biomaterials. Jan, 2012 | Pubmed ID: 22048005
We developed a three-dimensional assay prepared from primary breast cancer tissue and quantified tumor response to tamoxifen therapy. Freshly harvested breast cancer biopsies obtained at the time of curative surgical resection were fragmented and embedded into collagen I cushions. Changes in proliferation, apoptosis and tumor volume in response to tamoxifen treatment were quantified using image analysis software and optical projection tomography. Individual and collective invasion of epithelial cells into the surrounding collagen I was observed over the course of the experiment using phase contrast light microscopy and histopathological methods. Addition of tamoxifen to preparations derived from ER+ tumors demonstrated a range of response as measured by proliferative and apoptotic markers. In keeping with published data, tamoxifen reduced the percentage of apoptotic cells expressing cleaved caspase-3 (p = 0.02, Poisson regression analysis). Tamoxifen also reduced residual epithelial volume in ER+ tumors (p = 0.001, Mann-Whitney test), but not in ER low/- tumors (p = 0.78). Changes in tumor volume, as measured by optical projection tomography, allowed stratification into responsive and non-responsive tumors. The model mirrors observations of breast cancer response and histopathological changes to tamoxifen in neo-adjuvant trials. This assay provides a method of screening a battery of therapeutics against individual cancers, informing subsequent design of neo-adjuvant trials.